Our therapeutic projects include advanced cell and gene therapies, as well as drugs discovered by screening rare human cell types derived from stem cells.

Innovative cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production, as well as the provision of human cells for use in drug discovery.

Plasticell, Cell and Gene Therapy Catapult and Imperial College London obtain funding to develop manufacturing platform for allogeneic cell immunotherapies